title: Negative contractile reserve with low-dose dobutamine in patients with ischemic cardiomyopathy investigated by gated myocardial perfusion SPECT.
abstract: OBJECTIVE
  To investigate negative contractile responses in the left ventricle during low-dose dobutamine (LDD) gated single-photon emission computed tomography (SPECT) in patients with ischemic cardiomyopathy.
  
  
  METHODS
  Sixty-eight consecutive patients (mean age, 60 + or - 11 years; 7 male) with ischemic cardiomyopathy (i.e., left ventricular ejection fraction [LVEF] < or = 40%) were evaluated using gated-SPECT at rest and during LDD infusion. Associations between a negative contractile reserve (i.e., a > or = 1-grade improvement in wall thickening score with LDD infusion) and scintigraphic viability criteria and coronary angiography findings were analyzed.
  
  
  RESULTS
  Some 42.6% (29/68) of patients had a negative contractile reserve in one or more segments. In 14.7% (n=10), the LVEF decreased by > or = 4% with LDD. These patients had more segments with a negative contractile reserve (2.8 + or - 2.5 vs. 0.87 + or - 0.40; P=.042), and the cut-off value on receiver operating characteristic curve analysis was > or =2 segments with a negative contractile reserve (sensitivity 70%, specificity 74%, positive likelihood ratio 2.71, negative likelihood ratio 0.40). Some 94% (74/79) of segments with a negative contractile reserve were in viable myocardium (i.e. normal or viable on scintigraphy). Twelve of 17 segments with akinesia or severe hypokinesia and a negative contractile reserve satisfied scintigraphic viability criteria, with the majority (10/12) lying in territories supplied by a patent coronary artery.
  
  
  CONCLUSIONS
  A negative contractile reserve was not uncommon in patients with ischemic cardiomyopathy and was associated with a general decrease in left ventricular systolic function. It was observed mainly in myocardial segments that appeared viable on scintigraphy and were supplied by a patent coronary artery.
authors.affiliation: Servicio de Cardiologia, Area del Corazon, Hospital Universitario Vall d'Hebron, Universidad Autonoma de Barcelona, Pg. Vall d'Hebron, 119-129, 08035 Barcelona, Spain. jcandell@vhebron.net
authors.forename: Jaume
authors.initials: J
authors.lastname: Candell-Riera
authors.forename: Guillermo
authors.initials: G
authors.lastname: Romero-Farina
authors.forename: Marta
authors.initials: M
authors.lastname: Milá
authors.forename: Santiago
authors.initials: S
authors.lastname: Aguadé-Bruix
authors.forename: Gemma
authors.initials: G
authors.lastname: Cuberas
authors.forename: David
authors.initials: D
authors.lastname: García-Dorado
mesh_terms: D000368:Aged; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017023:Coronary Angiography; D004280:Dobutamine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D015637:Gated Blood-Pool Imaging; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction; D017202:Myocardial Ischemia / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000503:physiopathology; D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D015899:Tomography, Emission-Computed, Single-Photon; D016277:Ventricular Function, Left / Q000502:physiology
chemical_list: D002316:Cardiotonic Agents; D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D004280:Dobutamine; C078700:technetium tc-99m tetrofosmin